On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
The located developer material describes an investigational combination, not an approved medicine.
What the evidence shows
What the located primary material says
A July 2026 developer announcement describes plans to evaluate PDA+ together with bioelectric stimulation and other interventions for joint-related outcomes. It reports a proposed study approach, not completed controlled results. [1]
Why a combination cannot isolate an ingredient
The announced program may include exercise, nutrition, stimulation, and additional interventions. Even a future positive combination result would require careful design to show what PDA itself contributed. [1]
What remains unknown
This review did not identify completed controlled clinical results for the exact PDA preparation. Oral absorption, formulation equivalence, and claimed stability advantages remain unverified here.
Safety
What is not established
The announcement does not provide the clinical safety data needed to determine risks, interactions, or a reliable human exposure limit for PDA. [1]
Confirm the preparation
The announcement uses PDA+ within a proprietary program. It does not establish that every item sold as Pentadeca Arginate has the same composition. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [2]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [3]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Does a patent announcement demonstrate that it works?
No. A patent or proposed study documents an invention or plan; treatment benefit requires appropriate clinical evidence.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Leonhardt Ventures Announces Provisional Patent Application for Combination Osteoarthritis Therapy Featuring Pentadeca Arginate (PDA+)July 30, 2026 · Developer announcement; not peer-reviewed results
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.